CSL reaffirms its commitment to supply Australia with Novel Influenza A (H1N1) ‘Swine Flu’ Vaccine

CSL reaffirms its commitment to supply Australia with Novel Influenza A (H1N1) ‘Swine Flu’ Vaccine

Melbourne, Australia — 29/05/2009

CSL Biotherapies, a subsidiary of CSL Limited, Australia’s leading biopharmaceutical company, welcomes the Rudd Government’s recent announcement of its intention to place an order to supply 10 million Australians with a vaccine against Novel Influenza A (H1N1) or ‘swine flu’. 

CSL is well-placed to meet the needs of the Australian population in responding to the current epidemic. CSL will prepare candidate vaccine for use in clinical trials to determine the formulation and dosage of the vaccine. The first batches are expected to be manufactured by late July/ early August. The Australian government will determine how the vaccine will be deployed.

Download the Release:
PDF icon CSL reaffirms its commitment to supply Australia with Novel Influenza A (H1N1)
       ‘Swine Flu’ Vaccine
(0.23Mb)

 
Media Contact: 
Dr Rachel David
  Director, Public Affairs
  CSL Limited
  Telephone: +613 9389 1821
  Email: rachel.david@csl.com.au





© 2016 CSL Limited